Boothbay Fund Management’s BridgeBio Pharma BBIO Stock Holding History

Boothbay Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$544K	Sell	7,300 -9,700	-57%	-$679K	0.01%	1441
2026 Q1	$1.26M	Buy	+17,000	New	+$1.23M	0.02%	825
2025 Q2	–	Sell	-192,600	Closed	-$6.66M	–	1454
2025 Q1	$6.66M	Sell	192,600 -10,500	-5%	-$354K	0.18%	157
2024 Q4	$5.57M	Buy	+203,100	New	+$5.25M	0.14%	217
2024 Q3	–	Sell	-174,700	Closed	-$4.43M	–	1623
2024 Q2	$4.43M	Buy	174,700 +65,400	+60%	+$1.79M	0.1%	264
2024 Q1	$3.38M	Buy	+109,300	New	+$3.72M	0.07%	337
2023 Q4	–	Sell	-62,400	Closed	-$1.65M	–	1654
2023 Q3	$1.65M	Sell	62,400 -187,900	-75%	-$5.33M	0.04%	569
2023 Q2	$4.31M	Sell	250,300 -4,600	-2%	-$69.2K	0.09%	260
2023 Q1	$4.23M	Buy	+254,900	New	+$2.97M	0.09%	311
2022 Q3	–	Sell	-25,500	Closed	-$232K	–	2243
2022 Q2	$232K	Buy	+25,500	New	+$213K	0.01%	1636
2022 Q1	–	Sell	-28,200	Closed	-$470K	–	2269
2021 Q4	$470K	Buy	+28,200	New	+$1.19M	0.01%	1042

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Boothbay Fund Management's BBIO Position: Q2 2026 in Review

Boothbay Fund Management reduced its BridgeBio Pharma (BBIO) stake by 67% in Q2 2026, selling an estimated $2.19M and leaving 15,713 shares worth $1.17M. The position accounts for 0.02% of the portfolio, ranked #1000.

Boothbay Fund Management first reported a position in BBIO in Q4 2021 and has held it in 13 quarters since. The position peaked at $4.21M in Q4 2023. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Boothbay Fund Management held 15,713 shares of BridgeBio Pharma worth $1.17M as of Q2 2026.
Boothbay Fund Management sold 31,268 BridgeBio Pharma shares in Q2 2026, an estimated $2.19M.
BridgeBio Pharma made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #1000 holding.
Boothbay Fund Management first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 13 quarters since.
Boothbay Fund Management's BridgeBio Pharma position peaked at $4.21M in Q4 2023.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.